Harrow, Inc. (NASDAQ:HROW) is Private Capital Management LLC’s Largest Position

Private Capital Management LLC trimmed its position in Harrow, Inc. (NASDAQ:HROW) by 20.3% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,163,681 shares of the company’s stock after selling 551,170 shares during the period. Harrow comprises 19.4% of Private Capital Management LLC’s portfolio, making the stock its biggest holding. Private Capital Management LLC owned about 0.06% of Harrow worth $97,279,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Harrow by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock worth $57,000 after buying an additional 227 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in Harrow by 64.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 6,825 shares of the company’s stock worth $307,000 after acquiring an additional 2,668 shares during the period. Rice Hall James & Associates LLC boosted its stake in shares of Harrow by 23.1% during the 3rd quarter. Rice Hall James & Associates LLC now owns 314,881 shares of the company’s stock worth $14,157,000 after acquiring an additional 59,019 shares during the last quarter. Hills Bank & Trust Co bought a new stake in shares of Harrow during the 3rd quarter valued at $107,000. Finally, Principal Financial Group Inc. purchased a new stake in shares of Harrow in the 3rd quarter worth $329,000. 72.76% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. B. Riley lowered their target price on Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a research report on Wednesday, December 4th. HC Wainwright initiated coverage on Harrow in a research report on Thursday, February 6th. They set a “buy” rating and a $57.00 price objective on the stock.

Harrow Stock Down 2.6 %

HROW opened at $27.56 on Friday. The stock has a market cap of $981.55 million, a price-to-earnings ratio of -29.32 and a beta of 0.69. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. The firm’s fifty day moving average is $32.78 and its 200 day moving average is $40.13. Harrow, Inc. has a fifty-two week low of $9.30 and a fifty-two week high of $59.23.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.